Header Logo

Connection

Ajaypal Singh to Kidney Diseases

Back to Details
This is a "connection" page, showing publications Ajaypal Singh has written about Kidney Diseases.
Ajaypal Singh
Connection Strength
6.981
Kidney Diseases
  1. Recreational use of marijuana: Current experience and information for nephrologists. Nephrol News Issues. 2017 Apr; 31(4):32-33.
    View in: PubMed
    Score: 0.549
  2. The International Society of Nephrology (ISN) and the American Nephrologists of Indian Origin (ANIO) Online Clinical Nephropathology Certificate (CNC) program. Kidney Int. 2016 May; 89(5):966-968.
    View in: PubMed
    Score: 0.515
  3. Burden and predictors of hypertension in India: results of SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2014 Mar 06; 15:42.
    View in: PubMed
    Score: 0.443
  4. Consanguinity in Saudi Arabia: a unique opportunity for pediatric kidney research. Am J Kidney Dis. 2014 Feb; 63(2):304-10.
    View in: PubMed
    Score: 0.434
  5. Epidemiology of chronic kidney disease in the Kingdom of Saudi Arabia (SEEK-Saudi investigators) - a pilot study. Saudi J Kidney Dis Transpl. 2010 Nov; 21(6):1066-72.
    View in: PubMed
    Score: 0.352
  6. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):420-4.
    View in: PubMed
    Score: 0.348
  7. Message to the FDA on ESAs: REMS is not enough, more studies are needed. Clin J Am Soc Nephrol. 2010 Aug; 5(8):1355-8.
    View in: PubMed
    Score: 0.346
  8. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed? Am J Nephrol. 2010; 31(6):552-6; discussion 563-4.
    View in: PubMed
    Score: 0.341
  9. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.
    View in: PubMed
    Score: 0.336
  10. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol. 2010 Jan; 21(1):2-6.
    View in: PubMed
    Score: 0.332
  11. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010 Feb; 77(3):239-46.
    View in: PubMed
    Score: 0.328
  12. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol. 2009 Jul; 20(7):1436-41.
    View in: PubMed
    Score: 0.321
  13. Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatr Nephrol. 2009 Mar; 24(3):431-4.
    View in: PubMed
    Score: 0.299
  14. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 Sep; 74(6):791-8.
    View in: PubMed
    Score: 0.299
  15. Acute phosphate nephropathy. Kidney Int. 2009 May; 75(9):987-91.
    View in: PubMed
    Score: 0.299
  16. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008 Sep; 74(6):782-90.
    View in: PubMed
    Score: 0.298
  17. The nephrology quiz and questionnaire: 2006. Clin J Am Soc Nephrol. 2007 Nov; 2(6):1375-88.
    View in: PubMed
    Score: 0.285
  18. Anemia of chronic kidney disease: CHOIR and the FDA. Nat Clin Pract Nephrol. 2007 Aug; 3(8):406-7.
    View in: PubMed
    Score: 0.279
  19. Renal pathology practice globally: identifying needs and meeting the challenge. Kidney Int. 2019 08; 96(2):258-261.
    View in: PubMed
    Score: 0.161
  20. ESAs in dialysis patients: are you a hedgehog or a fox? J Am Soc Nephrol. 2010 Apr; 21(4):543-6.
    View in: PubMed
    Score: 0.084
  21. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant. 2010 May; 25(5):1567-75.
    View in: PubMed
    Score: 0.083
  22. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 2008 Dec; 74(12):1588-95.
    View in: PubMed
    Score: 0.076
  23. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocr Pract. 2007 May-Jun; 13(3):251-9.
    View in: PubMed
    Score: 0.069
  24. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar; 149(3):408-13.
    View in: PubMed
    Score: 0.059
  25. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology. 2013 Jan 29; 80(5):471-80.
    View in: PubMed
    Score: 0.026
  26. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.